Navigation Links
Dyadic Netherlands To Develop Enzymes For EU-Funded Research Consortium
Date:7/2/2012

JUPITER, Fla. and WAGENINGEN, The Netherlands, July 2, 2012 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the industrial enzyme, bioenergy, and biopharmaceutical industries, announced today that its research and development center in the Netherlands is a member of the Bio-Mimetic Project, a new multidisciplinary research consortium that has been awarded a EUR 3.5 million grant from the European Community's Seventh Framework Programme (FP7) of the European Community for Research, Technological Development and Demonstration Activities. The European consortium is commencing a three year research project entitled, "New Bio-Inspired Processes and Products from Renewable Feedstock" which will employ environmentally-friendly technologies to convert the renewable agricultural waste stream, lignin, into high value sustainable commercial products such as adhesives, detergents and cosmetics.

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO)

Wim van der Wilden, the General Manager of Dyadic Netherlands, stated, "We are very pleased to have the opportunity to work with such fine organizations on a highly innovative project where we can demonstrate the efficacy and productivity of our C1 technology to use green chemistry to find commercial applications for lignin. If successful, this project will be a promising step forward in using this renewable waste stream to replace traditional toxic, expensive and high energy consuming processes."

As part of the Bio-Mimetic Project, Dyadic Netherlands will receive approximately EUR 400,000 to develop enzymes using Dyadic's patented and proprietary C1 platform technology to degrade and modify lignin so that it can be used to create these high value commercial products.

Procter & Gamble Technical Centres Limited (P&G UK) will serve as the coordinator of the Bio-Mimetic Project Consortium which, in addition to Dyadic Netherlands, consists of the following participants:

  • Fraunhofer Institute IFAM (Germany)
  • The University of Rome Tor Vergata (Italy)
  • MAVI Sud s.r.l. (Italy)
  • Gulgi B.V. (The Netherlands)
  • Compagnie Industrielle de la Matiere Vegetale (CIMV)(France)
  • Procter & Gamble Eurocor N.V. (P&G Brussels Innovation Centre)(Belgium)
  • CiaoTech s.r.l (Italy)
  • The University of Manchester (United Kingdom)

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and others proteins for the bioenergy, industrial enzyme and biopharmaceutical industries.

Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the proteins which these technologies help produce. Please visit Dyadic's website at www.dyadic.com.

Dyadic Netherlands is a wholly owned subsidiary of Dyadic based in Wageningen, The Netherlands that conducts research and development activities for the benefit of Dyadic, its collaborators and customers. Please visit Dyadic Netherlands' website at www.dyadic.nl.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elekta and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital Sign Strategic Alliance to Further Cancer Research
2. World Renowned Inventor, Donald Spector, Develops Patent For Wireless Electric Acupuncture Patches
3. PrimeraDx Announces Commencement of Product Development Collaboration with Eli Lilly and Company
4. Spot On Sciences Awarded $1 Million DARPA Grant to Develop a Blood Sample Collection Device
5. Berg Pharma and the Parkinsons Institute ink R&D collaboration to drive disease understanding and accelerate therapeutic and diagnostic development in Parkinsons Disease
6. Sirnaomics Received NIH SBIR Grant for Developing Its Scarless Wound Healing siRNA Therapeutics
7. Developers: Deadline Approaching for Allscripts Million Hearts CDS Challenge
8. AIUM and AUA Guideline Development Leads To Practice Accreditation For Urologic Ultrasound
9. Omnyx Share Their Insight on Agile Software Development for Medical Devices
10. Softway Solutions Develops Award-Winning Health App for Texas Heart Institute
11. Tetra Discovery Partners Receives Major NIH Award To Develop New Alzheimers Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
(Date:5/29/2017)... Israel, May 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... technology which enables the functional selection of stem cells, ... for the first quarter ended March 31 st , ... our accomplishments in the first quarter of 2017," said ... quarter, we announced the treatment of the first blood ...
(Date:5/22/2017)... VALLEY COTTAGE, N.Y. , May 22, 2017 ... natural antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of ... in plain English, the results of a clinical ... after one year treatment with Gene-Eden-VIR/Novirin in individuals ... is important to note that there are no ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... PureLife Dental is pleased ... separator supplier for CDA members. As part of the amalgam separator endorsement, all CDA ... saving more than $400 off the retail value. This partnership between PureLife and CDA ...
(Date:6/23/2017)... ... 2017 , ... Ulster University, Magee Campus in Northern Ireland is hosting The ... to present to graduate students exciting new and innovative hope research based on iFred’s ... The Health Improvement Service of the Western Health & Social Care Trust (WHSCT) in ...
(Date:6/23/2017)... ... June 23, 2017 , ... All-Star Insurance, a family managed agency that offers ... Texas, is announcing the launch of a new charity drive to benefit women in ... United States reveal that an estimated 252, 710 new cases of invasive or high ...
(Date:6/22/2017)... ... ... Branches, Inc. has been partnering with The Miami Foundation for over 9 ... focused on providing opportunity to low-income families and breaking the cycle of generational poverty. ... to support its , Climb to College & Career initiative which focuses on postsecondary ...
(Date:6/22/2017)... ... June 22, 2017 , ... Groove Ring is excited ... about their high performance silicon wedding bands and all-purpose rings. Whether you’re an athlete, ... silicone rings designed just for you. , From the rock face to the auto ...
Breaking Medicine News(10 mins):